All News

Your daily dose of the clinical news you may have missed.

In November 2024, an FDA advisory committee said the benefits of sotagliflozin do not outweigh the risks in adults with type 1 diabetes and chronic kidney disease.

Agitation affects at least one half of adults with Alzheimer disease; geriatric psychiatrist Grossberg explains the symptoms and new treatments in this year's video series.

Daily step counts of 5000 or more corresponded with fewer depressive symptoms, according to a recent systematic review and meta-analysis.

President of the Obesity Medicine Association discusses a recent joint statement from the OMA and 4 other organizations calling for inclusion of patients with obesity in drug research.

NX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA.

Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.

Axsome plans to submit a New Drug Application to the FDA in the second half of 2025 that is based on positive results from 4 pivotal phase 3 clinical trails and long-term data.

Your daily dose of the clinical news you may have missed.

Substances of choice used in the previous 12 months were alcohol, nicotine vaping, and cannabis but the trends among the 8th, 10th, and 12th graders are very encouraging.

Angela Fitch, MD, discusses the importance of clinician education in addressing obesity with patients.

The 5 summaries that follow cover harmful ingredients, associated health risks, industry marketing tactics, and current regulatory efforts.

The FDA has approved the first generic once-daily GLP-1 injection for the improvement of glycemic control for type 2 diabetes in patients 10 years and up.

Your daily dose of the clinical news you may have missed.

The black box warning, the agency's most prominent alert, follows earlier additions to the original fezolinetant label about hepatic injury and regular LFT testing.

This marks the second indication for tirzepatide in just more than a year, following its November 2023 approval for adults with obesity or overweight and weight-related medical problems.

People with hypertension who adhered to the mobile app demonstrated well-controlled blood pressure over a 12-week observational period.

The first in class CRF-1 receptor antagonist allows people with CAH to reduce glucocorticoid doses while androgen levels are maintained or improved.